Wuxi Biologics Gets Good Manufacturing Practice Certification From Brazils Anvisa

Wuxi Biologics, A Global Company With Leading Open-Access Biologics Technology Platforms, Announced That It Has Received The Good Manufacturing Practice (Gmp) Certification From Brazil'S AgÊNcia Nacional De VigilÂNcia SanitÁRia (Anvisa). The Positive Assessment From Anvisa Reaffirms Wuxi Biologics' Strong Commitment To Offering Partners A Global Manufacturing Network Of The Highest Standard.This Is Wuxi Biologics' Third Gmp Certification From Drug Regulatory Authorities, And Distinguishes It As The First Company In China To Receive Authorizations From The Us Food And Drug Administration (Fda), European Medicines Agency (Ema) And Anvisa To Manufacture Biologics. To Date, Wuxi Biologics' Facilities In Wuxi City, Shanghai And Suzhou Have Passed A Total Of Six Gmp Inspections Conducted By These Regulatory Agencies."We Are Very Excited To Have Reached Another Regulatory Milestone During This Challenging Year. This Achievement Once Again Demonstrates Wuxi Biologics' High-Quality Services, Which Have Been Widely Recognized By Regulatory Authorities. We Owe This Achievement To Our Partners' Trust In Our Capabilities And Our Team'S Tireless Commitment To Excellence," Commented Dr. Chris Chen, Ceo Of Wuxi Biologics. "As Outsourcing Demand Increases Around The World, We Have Made Huge Strides In Expanding Our Services Globally And Plan To Increase Our Total Biomanufacturing Capacity To 300,000 Liters After 2023. Wuxi Biologics Will Continue To Enable Our Global Partners Throughout The Development And Manufacturing Process To Provide Life-Saving Treatments To Patients Worldwide."Wuxi Biologics, A Hong Kong-Listed Company, Is A Leading Global Open-Access Biologics Technology Platform Offering End-To-End Solutions To Empower Organizations To Discover, Develop, And Manufacture Biologics From Concept To Commercial Manufacturing.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!